<DOC>
	<DOCNO>NCT01953913</DOCNO>
	<brief_summary>Primary objective trial evaluate safety afatinib patient locally advanced metastatic non-small cell lung cancer ( NSCLC ) harbor EGFR ( Epidermal growth factor receptor ) mutation ( ) never treat EGFR-TKI ( tyrosine kinase inhibitor ) . Secondary objective ass time symptomatic progression ( judged investigator ) .</brief_summary>
	<brief_title>Afatinib ( BIBW 2992 ) Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : locally advance metastatic Nonsmall Cell Lung Cancer ( NSCLC ) presence Epidermal Growth Factor Receptor ( EGFR ) mutation tumor biopsy male female patient age 18 year old adequate organ function , define follow : 1 . Absolute Neutrophil Count ( ANC ) &gt; 1500/mm3 . ( ANC &gt; 1000/mm3 may consider special circumstance benign cyclical neutropenia judge investigator discussion sponsor ) . 2 . Platelet count &gt; 75,000/mm3 3 . Serum creatinine &lt; 1.5 time upper limit normal 4 . Total Bilirubin &lt; 1.5 time upper limit ( institutional ) normal ( Patients Gilbert多s syndrome total bilirubin must &lt; 4 time institutional upper limit normal ) . 5 . Aspartate Amino Transferase ( AST ) Alanine Amino Transferase ( ALT ) &lt; three time upper limit ( institutional ) normal ( ULN ) ( relate liver metastasis &lt; five time ULN ) . 5 ) ECOG score 0 多 2 6 ) write informed consent patient guardian prior admission trial consistent International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) guideline local law . Exclusion criterion : prior treatment EGFR tyrosine kinase inhibitor ( TKI ) use anticancer treatment within 2 week prior start trial treatment ( continue use antiandrogens / gonadorelin analogue treatment prostate cancer permit ) radiotherapy within 4 week prior drug administration except follow : 1. palliative radiation organ chest may allow 2 week prior drug administration , 2. single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol . major surgery within 4 week day 1 first dose afatinib . At least 7 day elapse since minor surgical procedure include placement access device fine needle aspiration least 14 day diagnostic palliative videoassisted thoracoscopic surgery ( VATS ) . know hypersensitivity afatinib excipients history presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure New York Heart Association ( NYHA ) classification &gt; 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior start trial treatment . Women ChildBearing Potential ( WOCBP ) men able father child , unwilling abstinent use medically acceptable method contraception trial entry least 4 week treatment end . Adequate method contraception Women ChildBearing Potential . Perimenopausal woman must amenorrhoeic least 24 month consider nonchildbearing potential . childbearing potential ( see Section 4.2.3 ) : 1. nurse 2. pregnant 3. use acceptable method birth control , plan continue use method throughout trial and/or agree submit pregnancy test require protocol history coexist condition , opinion investigator , would compromise patient多s ability comply trial interfere evaluation safety trial drug previous concomitant malignancy sit , except effectively treat nonmelanoma skin cancer , carcinoma situ cervix , ductal carcinoma situ effectively treat malignancy remission 3 year consider cure . require treatment prohibit concomitant medication list , stop duration trial participation know preexist interstitial lung disease presence poorly control gastrointestinal disorder could affect absorption trial drug ( e.g . Crohn多s disease , ulcerative colitis , malabsorption , CTC grade =2 diarrhoea aetiology ) base investigator assessment . Known active hepatitis B infection ( define presence Hepatitis B ( HepB ) sAg and/or HepB DNA ) , active Hepatitis C ( HEP C ) infection ( define presence Hep C RNA ) and/or know Human Immunodeficiency Virus ( HIV ) carrier . meningeal carcinomatosis symptomatic brain metastasis ( patient brain metastasis , previously treat , eligible provide asymptomatic brain metastasis least 4 week stable dos medication )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>